Cargando…

Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling

Rationale: Hepatocellular carcinoma (HCC) has been increasingly recognized in nonalcoholic steatohepatitis (NASH) patients. Fibroblast growth factor 21 (FGF21) is reported to prevent NASH and delay HCC development. In this study, the effects of FGF21 on NASH progression and NASH-HCC transition and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Qianqian, Martin, Robert C., Shi, Xiaoju, Pandit, Harshul, Yu, Youxi, Liu, Xingkai, Guo, Wei, Tan, Min, Bai, Ou, Meng, Xin, Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481424/ https://www.ncbi.nlm.nih.gov/pubmed/32929325 http://dx.doi.org/10.7150/thno.45988

Ejemplares similares

Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice
por: Yu, Youxi, et al.
Publicado: (2021)

Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice
por: Pandit, Harshul, et al.
Publicado: (2020)

FGF19 and FGF21: In NASH we trust
por: Talukdar, Saswata, et al.
Publicado: (2020)

Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
por: Ge, Chenxu, et al.
Publicado: (2022)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Head Over Hepatocytes for FGF21
por: Potthoff, Matthew J., et al.
Publicado: (2014)

FGF9 Recruits β‐Catenin to Increase Hepatic ECM Synthesis and Promote NASH‐Driven HCC
por: Zhang, Lei, et al.
Publicado: (2023)

FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
por: Henriksson, Emma, et al.
Publicado: (2020)

Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC
por: Zhang, Yueqi, et al.
Publicado: (2021)

Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver
por: Cui, Guozhen, et al.
Publicado: (2018)

Mitochondrial Dysfunction in the Transition from NASH to HCC
por: Léveillé, Mélissa, et al.
Publicado: (2019)

Metformin Stimulates FGF21 Expression in Primary Hepatocytes
por: Nygaard, Eva B., et al.
Publicado: (2012)

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
por: Yu, Simiao, et al.
Publicado: (2022)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
por: Pfister, Dominik, et al.
Publicado: (2021)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Reduced Oxidative Stress and Enhanced FGF21 Formation in Livers of Endurance-Exercised Rats with Diet-Induced NASH
por: Henkel, Janin, et al.
Publicado: (2019)

Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression
por: Kim, Hye Young, et al.
Publicado: (2022)

Serological biomarkers associate ultrasound characteristics of steatohepatitis in mice with liver cancer
por: Cui, Guozhen, et al.
Publicado: (2018)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
por: Shao, Gaoxuan, et al.
Publicado: (2022)

Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
por: Boslem, Ebru, et al.
Publicado: (2023)

Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH
por: Dong, Jinrui, et al.
Publicado: (2021)

Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH
por: Bonnet, Laurianne, et al.
Publicado: (2022)

Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
por: Myint, Melissa, et al.
Publicado: (2023)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
por: De Minicis, Samuele, et al.
Publicado: (2014)

Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
por: Grohmann, Marcus, et al.
Publicado: (2018)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

β-Hydroxybutyrate upregulates FGF21 expression through inhibition of histone deacetylases in hepatocytes
por: Yan, Aili, et al.
Publicado: (2022)

TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
por: Shepard, Christopher R.
Publicado: (2021)

Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet
por: Singhal, Garima, et al.
Publicado: (2018)

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
por: Li, Yan, et al.
Publicado: (2022)

FGF2 cooperates with IL-17 to promote autoimmune inflammation
por: Shao, Xinrui, et al.
Publicado: (2017)

HIF2α Activation in NASH: A New Force Pushing Toward HCC
por: Clavería-Cabello, Alex, et al.
Publicado: (2021)

A maternal high-fat diet induces fetal origins of NASH-HCC in mice
por: Takiyama, Takao, et al.
Publicado: (2022)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
por: Li, Xinzhi, et al.
Publicado: (2022)

FGF19 subfamily members: FGF19 and FGF21
por: Dolegowska, Katarzyna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b0bt9lj3coa8an43amjjd4fvl8